Laminin receptor in lymph node negative breast carcinoma

Mehrdad Nadji, Mehdi Nassiri, Manuel Fresno, Edward Terzian, Azorides R Morales

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

BACKGROUND. Expression of 67 kD laminin binding protein, 67LR, is reported to be associated with invasive and metastatic phenotypes in several types of human malignancies. In mammary carcinomas, however, the biologic role of 67LR has been less clear. The authors explored the potential biologic significance of expression of 67LR in 148 patients with axillary lymph node negative breast carcinoma. METHODS. Formalin fixed, paraffin embedded histologic sections were immunohistochemically evaluated for 67LR using monoclonal antibody MLuC5. The staining results were correlated with morphologic data as well as with estrogen receptor content and p53 product accumulation. RESULTS. There were statistically significant correlations between positivity for 67LR and lower histologic grade (P = 0.003), lower nuclear grade (P = 0.002), positivity for estrogen receptor (P = 0.003), and lack of p53 abnormality (P < 0.001). Expression of 67LR had no independent effect on the disease free or overall survival of lymph node negative patients with breast carcinoma. Nevertheless, in the subgroup of 67LR positive patients, positivity for estrogen receptor was associated with significantly longer overall survival (P = 0.008). CONCLUSIONS. The data from this study suggest that tissue expression of 67LR, as detected by antibody MLuC5, is associated with better differentiated, less aggressive forms of axillary lymph node negative breast carcinoma.

Original languageEnglish
Pages (from-to)432-436
Number of pages5
JournalCancer
Volume85
Issue number2
DOIs
StatePublished - Feb 2 1999

Fingerprint

Laminin Receptors
Lymph Nodes
Estrogen Receptors
Breast Neoplasms
Laminin
Paraffin
Formaldehyde
Carrier Proteins
Monoclonal Antibodies
Staining and Labeling
Phenotype
Survival
Antibodies
Neoplasms

Keywords

  • 67LR
  • Breast carcinoma
  • Immunohistochemistry
  • Laminin receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Laminin receptor in lymph node negative breast carcinoma. / Nadji, Mehrdad; Nassiri, Mehdi; Fresno, Manuel; Terzian, Edward; Morales, Azorides R.

In: Cancer, Vol. 85, No. 2, 02.02.1999, p. 432-436.

Research output: Contribution to journalArticle

Nadji, Mehrdad ; Nassiri, Mehdi ; Fresno, Manuel ; Terzian, Edward ; Morales, Azorides R. / Laminin receptor in lymph node negative breast carcinoma. In: Cancer. 1999 ; Vol. 85, No. 2. pp. 432-436.
@article{d886f1efa1af4f7ea35b3fa214b25d4f,
title = "Laminin receptor in lymph node negative breast carcinoma",
abstract = "BACKGROUND. Expression of 67 kD laminin binding protein, 67LR, is reported to be associated with invasive and metastatic phenotypes in several types of human malignancies. In mammary carcinomas, however, the biologic role of 67LR has been less clear. The authors explored the potential biologic significance of expression of 67LR in 148 patients with axillary lymph node negative breast carcinoma. METHODS. Formalin fixed, paraffin embedded histologic sections were immunohistochemically evaluated for 67LR using monoclonal antibody MLuC5. The staining results were correlated with morphologic data as well as with estrogen receptor content and p53 product accumulation. RESULTS. There were statistically significant correlations between positivity for 67LR and lower histologic grade (P = 0.003), lower nuclear grade (P = 0.002), positivity for estrogen receptor (P = 0.003), and lack of p53 abnormality (P < 0.001). Expression of 67LR had no independent effect on the disease free or overall survival of lymph node negative patients with breast carcinoma. Nevertheless, in the subgroup of 67LR positive patients, positivity for estrogen receptor was associated with significantly longer overall survival (P = 0.008). CONCLUSIONS. The data from this study suggest that tissue expression of 67LR, as detected by antibody MLuC5, is associated with better differentiated, less aggressive forms of axillary lymph node negative breast carcinoma.",
keywords = "67LR, Breast carcinoma, Immunohistochemistry, Laminin receptor",
author = "Mehrdad Nadji and Mehdi Nassiri and Manuel Fresno and Edward Terzian and Morales, {Azorides R}",
year = "1999",
month = "2",
day = "2",
doi = "10.1002/(SICI)1097-0142(19990115)85:2<432::AID-CNCR22>3.0.CO;2-J",
language = "English",
volume = "85",
pages = "432--436",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Laminin receptor in lymph node negative breast carcinoma

AU - Nadji, Mehrdad

AU - Nassiri, Mehdi

AU - Fresno, Manuel

AU - Terzian, Edward

AU - Morales, Azorides R

PY - 1999/2/2

Y1 - 1999/2/2

N2 - BACKGROUND. Expression of 67 kD laminin binding protein, 67LR, is reported to be associated with invasive and metastatic phenotypes in several types of human malignancies. In mammary carcinomas, however, the biologic role of 67LR has been less clear. The authors explored the potential biologic significance of expression of 67LR in 148 patients with axillary lymph node negative breast carcinoma. METHODS. Formalin fixed, paraffin embedded histologic sections were immunohistochemically evaluated for 67LR using monoclonal antibody MLuC5. The staining results were correlated with morphologic data as well as with estrogen receptor content and p53 product accumulation. RESULTS. There were statistically significant correlations between positivity for 67LR and lower histologic grade (P = 0.003), lower nuclear grade (P = 0.002), positivity for estrogen receptor (P = 0.003), and lack of p53 abnormality (P < 0.001). Expression of 67LR had no independent effect on the disease free or overall survival of lymph node negative patients with breast carcinoma. Nevertheless, in the subgroup of 67LR positive patients, positivity for estrogen receptor was associated with significantly longer overall survival (P = 0.008). CONCLUSIONS. The data from this study suggest that tissue expression of 67LR, as detected by antibody MLuC5, is associated with better differentiated, less aggressive forms of axillary lymph node negative breast carcinoma.

AB - BACKGROUND. Expression of 67 kD laminin binding protein, 67LR, is reported to be associated with invasive and metastatic phenotypes in several types of human malignancies. In mammary carcinomas, however, the biologic role of 67LR has been less clear. The authors explored the potential biologic significance of expression of 67LR in 148 patients with axillary lymph node negative breast carcinoma. METHODS. Formalin fixed, paraffin embedded histologic sections were immunohistochemically evaluated for 67LR using monoclonal antibody MLuC5. The staining results were correlated with morphologic data as well as with estrogen receptor content and p53 product accumulation. RESULTS. There were statistically significant correlations between positivity for 67LR and lower histologic grade (P = 0.003), lower nuclear grade (P = 0.002), positivity for estrogen receptor (P = 0.003), and lack of p53 abnormality (P < 0.001). Expression of 67LR had no independent effect on the disease free or overall survival of lymph node negative patients with breast carcinoma. Nevertheless, in the subgroup of 67LR positive patients, positivity for estrogen receptor was associated with significantly longer overall survival (P = 0.008). CONCLUSIONS. The data from this study suggest that tissue expression of 67LR, as detected by antibody MLuC5, is associated with better differentiated, less aggressive forms of axillary lymph node negative breast carcinoma.

KW - 67LR

KW - Breast carcinoma

KW - Immunohistochemistry

KW - Laminin receptor

UR - http://www.scopus.com/inward/record.url?scp=0032917457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032917457&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19990115)85:2<432::AID-CNCR22>3.0.CO;2-J

DO - 10.1002/(SICI)1097-0142(19990115)85:2<432::AID-CNCR22>3.0.CO;2-J

M3 - Article

VL - 85

SP - 432

EP - 436

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 2

ER -